Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. (OTCQX: DYAI) is a global biotechnology company renowned for its pioneering work in gene expression systems. The company has developed the C1 Expression System, a patented and proprietary technology utilizing the Thermothelomyces heterothallica fungus, which has set new standards in the production of commercial quantities of industrial enzymes and other proteins. This innovative platform is licensed to industry giants like Abengoa Bioenergy, BASF, and Codexis for various non-pharmaceutical applications.
Core Business
Dyadic's core business revolves around the advancement and application of the C1 Expression System. This platform is instrumental in producing biologic vaccines and drugs at a faster rate, in larger volumes, and at a lower cost, thereby making healthcare more accessible and affordable. By enhancing protein production capabilities, Dyadic aims to meet the growing demands of drug developers and manufacturers, ultimately improving patient care and saving lives.
Recent Achievements and Current Projects
Dyadic has made significant strides in the biotechnology sector. The company has successfully showcased the efficiency of the C1 Expression System in various industrial applications. Currently, Dyadic is focusing on expanding its influence in the pharmaceutical sector, aiming to leverage C1's potential for large-scale production of human and animal vaccines and therapeutics.
Financial Condition
With a solid financial foundation, Dyadic continues to invest in research and development, ensuring the continuous improvement of its gene expression technology. The company's partnerships and licensing agreements with major industry players underscore its financial stability and growth potential.
Partnerships and Collaborations
Dyadic's collaborative efforts with companies like Abengoa Bioenergy, BASF, and Codexis highlight its pivotal role in the biotechnology landscape. These partnerships enable Dyadic to expand the application of the C1 Expression System beyond pharmaceuticals, touching sectors such as food, nutrition, and wellness.
Products and Services
Dyadic's primary product, the C1 Expression System, is a game-changer in gene expression and protein production. The company is dedicated to advancing this technology to meet the evolving needs of the biopharmaceutical industry, ensuring more efficient and cost-effective production processes.
Contact Information
For further information, inquiries can be directed to Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com.
Dyadic International (NASDAQ: DYAI) has received a $3 million grant from the Gates Foundation to develop cost-effective monoclonal antibodies (mAbs) for RSV and malaria using its C1 platform technology. The initiative aims to provide affordable therapeutics for underserved populations, particularly in low-income and middle-income countries (LMICs). RSV causes 3.2-36 million hospitalizations and over 100,000 deaths annually, while malaria affected 249 million cases and caused 608,000 deaths globally in 2022. The C1 platform is designed to accelerate development, reduce production costs, and improve scalability of biologic vaccines and therapeutics. Dyadic plans to commercialize successful antibodies through licensure to expand access to affordable treatment options globally.
Dyadic International (NASDAQ: DYAI) reported strong Q3 2024 financial results, with revenue increasing to $1.958M from $397K year-over-year. The growth was primarily driven by a $1M milestone payment for animal-free recombinant albumin products and a $425K success fee from a dairy enzyme collaboration. The company maintained a solid cash position of $10M as of September 30, 2024.
Key developments include successful expression of antigens for HIV, HPV, and RSV vaccines, and a highly productive C1-produced ferritin nanoparticle Mpox antigen achieving 4.5 g/L in 7 days. Operating loss decreased to $203K from $1.72M in the previous year, reflecting improved operational efficiency and revenue growth.
Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming Third Quarter 2024 financial results release and corporate update conference call scheduled for Tuesday, November 12, 2024, at 5:00 p.m. Eastern Time. The conference call will be accessible via toll-free and international dial-in numbers, with a webcast option available. Investors can submit questions for the Q&A session via email to ir@dyadic.com prior to the call.
Dyadic International (NASDAQ: DYAI) has announced its participation in several key industry events worldwide, demonstrating its commitment to global expansion and advancing biomanufacturing. The company will attend the Developing Countries Vaccine Manufacturers Network (DCVMN) Int'l Annual Meeting in São Paulo, Brazil (Oct 16-18, 2024), the World Vaccine Congress Europe in Barcelona (Oct 29-31, 2024), and BIO-Europe in Stockholm, Sweden (Nov 4-6, 2024).
At the World Vaccine Congress Europe, Dyadic will present on 'C1 Technology: Redefining Biomanufacturing for a Healthier Tomorrow' on October 30. The company aims to showcase the scalability, speed, and cost advantages of its proprietary C1 and Dapibus™ technology platforms for producing vaccines, therapeutics, and non-pharmaceutical products. These events provide opportunities for Dyadic to foster collaborations and highlight its innovative approaches in biotechnology.
Dyadic International, Inc. (NASDAQ: DYAI) has provided an update on its business progress in alternative proteins and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024. The company will showcase its C1 and Dapibus™ microbial platforms for efficient, large-scale protein manufacturing.
Key developments include:
- Proliant Health and Biologicals partnership expected to launch animal-free recombinant albumin in H1 2025
- Completion of DNase-I protein development with ongoing product sampling
- High productivity achieved in recombinant bovine transferrin project
- Ongoing development of recombinant human lactoferrin and bovine growth factor
Dyadic is advancing partnerships in the alternative protein market while progressing its C1 platform in animal and human health markets.
Dyadic International (NASDAQ: DYAI) announced its Q2 2024 financial results and recent company progress. Key highlights include:
- Entered a development and commercialization partnership with Proliant Health and Biologicals for animal-free recombinant albumin products
- Joined a development agreement with a Top 10 global dairy company for non-animal alpha-lactalbumin
- Provided samples of C1-produced avian influenza 'Bird Flu' antigen for potential use in poultry and cattle vaccines
- Demonstrated strong immune response in animal studies for C1-produced H5 Clade 2.3.3.4.b A/Astrakhan recombinant ferritin nanoparticle vaccine candidate
- Cash and investment grade securities of $10.1 million as of June 30, 2024
- Q2 2024 revenue decreased to $386,000 from $837,000 in Q2 2023
- Net loss for Q2 2024 was $2,045,000 or $(0.07) per share
Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein production for vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming second quarter 2024 financial results release and corporate update conference call. The event is scheduled for Tuesday, August 13, 2024, at 5:00 p.m. Eastern Time.
Investors and interested parties can access the call via toll-free (877-407-0784) or international (+1-201-689-8560) numbers, using the Conference ID: 13743569. A webcast will also be available, with an archive accessible on Dyadic's Investor Relations website within 24 hours after the live event. Participants are encouraged to submit questions for the Q&A session via email to ir@dyadic.com prior to the call.
Dyadic International (NASDAQ: DYAI) has announced a strategic partnership with Proliant Health and Biologicals to develop and commercialize recombinant albumin products.
Under the agreement, Dyadic will receive an upfront milestone payment of $1.5 million and a share of the profits from PHB's sales of animal-free recombinant albumin, made using Dyadic's microbial platforms. The partnership aims to launch its first product in the first half of 2025, targeting the $6 billion serum albumin market.
Dyadic's COO, Joe Hazelton, highlighted the partnership as a strategic move to generate revenue in the Alternative Proteins segment, leveraging Dyadic's protein production technology and PHB's market presence. PHB's CEO, Chris Detzel, emphasized the growing demand for alternative protein sources and the partnership's potential for product innovation in the life sciences industry.
Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale production of proteins for vaccines, therapeutics, and other applications, announced its participation in several industry events in June 2024.
These events include BIO 2024 at the San Diego Convention Center from June 3-6, where Dyadic will present on June 5 at 11:00 AM PT. Additionally, Dyadic will attend the Future Food Tech-Alt Proteins conference in Chicago from June 17-18, and the 2024 NIIMBL National Meeting in Washington, DC from June 25-27.
These appearances are part of Dyadic's strategy to engage with industry stakeholders and showcase their innovations. Meetings can be scheduled with Dyadic's management by contacting Heidi Zosiak.
Dyadic International (NASDAQ: DYAI) released its Q1 2024 results, reporting a net loss of $2.01 million or $(0.07) per share, compared to a net loss of $0.96 million or $(0.03) per share a year ago. Revenue for the quarter decreased to $335,000 from $934,000 in Q1 2023. Cash and equivalents stood at $12.1 million as of March 31, 2024.
Key advancements include positive Phase 1 results for DYAI-100, a COVID-19 booster vaccine, and multiple collaborations on vaccine and antibody projects. The company also expanded its work in animal health and alternative proteins sectors.
Strategic partnerships were formed to develop rabies vaccines and alternative proteins. The financial standing was bolstered by a $6.0 million convertible note. Leadership changes include Patrick Lucy as Board Chairman and Joe Hazelton as COO.
FAQ
What is the current stock price of Dyadic International (DYAI)?
What is the market cap of Dyadic International (DYAI)?
What does Dyadic International, Inc. do?
What is the C1 Expression System?
Who are Dyadic's partners?
What sectors does Dyadic serve?
How does Dyadic's C1 Expression System benefit the healthcare sector?
Where is Dyadic International, Inc. headquartered?
What recent projects is Dyadic working on?
How can I contact Dyadic for more information?
What is Dyadic's stock symbol?
What is the main goal of Dyadic International, Inc.?
